Literature DB >> 29302062

Parkinson disease in 2017: Changing views after 200 years of Parkinson disease.

Walter Maetzler1, Daniela Berg1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29302062     DOI: 10.1038/nrneurol.2017.183

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Impaired dual tasking in Parkinson's disease is associated with reduced focusing of cortico-striatal activity.

Authors:  Freek Nieuwhof; Bastiaan R Bloem; Miriam F Reelick; Esther Aarts; Inbal Maidan; Anat Mirelman; Jeffrey M Hausdorff; Ivan Toni; Rick C Helmich
Journal:  Brain       Date:  2017-05-01       Impact factor: 13.501

2.  Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts.

Authors:  Andrea Pilotto; Sebastian Heinzel; Ulrike Suenkel; Stefanie Lerche; Kathrin Brockmann; Benjamin Roeben; Eva Schaeffer; Isabel Wurster; Rezzak Yilmaz; Inga Liepelt-Scarfone; Anna-Katharina von Thaler; Florian G Metzger; Gerhard W Eschweiler; Ron B Postuma; Walter Maetzler; Daniela Berg
Journal:  Mov Disord       Date:  2017-05-16       Impact factor: 10.338

Review 3.  Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Authors:  J A Obeso; M Stamelou; C G Goetz; W Poewe; A E Lang; D Weintraub; D Burn; G M Halliday; E Bezard; S Przedborski; S Lehericy; D J Brooks; J C Rothwell; M Hallett; M R DeLong; C Marras; C M Tanner; G W Ross; J W Langston; C Klein; V Bonifati; J Jankovic; A M Lozano; G Deuschl; H Bergman; E Tolosa; M Rodriguez-Violante; S Fahn; R B Postuma; D Berg; K Marek; D G Standaert; D J Surmeier; C W Olanow; J H Kordower; P Calabresi; A H V Schapira; A J Stoessl
Journal:  Mov Disord       Date:  2017-09       Impact factor: 10.338

4.  Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases.

Authors:  Aree Witoelar; Iris E Jansen; Yunpeng Wang; Rahul S Desikan; J Raphael Gibbs; Cornelis Blauwendraat; Wesley K Thompson; Dena G Hernandez; Srdjan Djurovic; Andrew J Schork; Francesco Bettella; David Ellinghaus; Andre Franke; Benedicte A Lie; Linda K McEvoy; Tom H Karlsen; Suzanne Lesage; Huw R Morris; Alexis Brice; Nicholas W Wood; Peter Heutink; John Hardy; Andrew B Singleton; Anders M Dale; Thomas Gasser; Ole A Andreassen; Manu Sharma
Journal:  JAMA Neurol       Date:  2017-07-01       Impact factor: 18.302

5.  Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.

Authors:  Seyed-Mohammad Fereshtehnejad; Yashar Zeighami; Alain Dagher; Ronald B Postuma
Journal:  Brain       Date:  2017-07-01       Impact factor: 13.501

Review 6.  Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.

Authors:  Alberto J Espay; Michael A Schwarzschild; Caroline M Tanner; Hubert H Fernandez; David K Simon; James B Leverenz; Aristide Merola; Alice Chen-Plotkin; Patrik Brundin; Marcelo A Kauffman; Roberto Erro; Karl Kieburtz; Daniel Woo; Eric A Macklin; David G Standaert; Anthony E Lang
Journal:  Mov Disord       Date:  2017-02-24       Impact factor: 10.338

7.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Authors:  Shuchi Mittal; Kjetil Bjørnevik; Doo Soon Im; Adrian Flierl; Xianjun Dong; Joseph J Locascio; Kristine M Abo; Elizabeth Long; Ming Jin; Bing Xu; Yang K Xiang; Jean-Christophe Rochet; Anders Engeland; Patrizia Rizzu; Peter Heutink; Tim Bartels; Dennis J Selkoe; Barbara J Caldarone; Marcie A Glicksman; Vikram Khurana; Birgitt Schüle; David S Park; Trond Riise; Clemens R Scherzer
Journal:  Science       Date:  2017-09-01       Impact factor: 47.728

8.  Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.

Authors:  Emily J Henderson; Stephen R Lord; Matthew A Brodie; Daisy M Gaunt; Andrew D Lawrence; Jacqueline C T Close; A L Whone; Y Ben-Shlomo
Journal:  Lancet Neurol       Date:  2016-01-13       Impact factor: 44.182

Review 9.  Health-Related Quality of Life in patients with Parkinson's disease--A systematic review based on the ICF model.

Authors:  Janet M T van Uem; Johan Marinus; Colleen Canning; Rob van Lummel; Richard Dodel; Inga Liepelt-Scarfone; Daniela Berg; Meg E Morris; Walter Maetzler
Journal:  Neurosci Biobehav Rev       Date:  2015-12-02       Impact factor: 8.989

10.  A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease.

Authors:  Elvira Mass; Christian E Jacome-Galarza; Thomas Blank; Tomi Lazarov; Benjamin H Durham; Neval Ozkaya; Alessandro Pastore; Marius Schwabenland; Young Rock Chung; Marc K Rosenblum; Marco Prinz; Omar Abdel-Wahab; Frederic Geissmann
Journal:  Nature       Date:  2017-08-30       Impact factor: 49.962

  10 in total
  5 in total

1.  Inorganic Polyphosphate, Mitochondria, and Neurodegeneration.

Authors:  Pedro Urquiza; Maria E Solesio
Journal:  Prog Mol Subcell Biol       Date:  2022

2.  Overdosing on iron: Elevated iron and degenerative brain disorders.

Authors:  Santosh R D'Mello; Mark C Kindy
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-02

3.  Osteocalcin Ameliorates Motor Dysfunction in a 6-Hydroxydopamine-Induced Parkinson's Disease Rat Model Through AKT/GSK3β Signaling.

Authors:  Xing-Zhi Guo; Chang Shan; Yan-Fang Hou; Geng Zhu; Bei Tao; Li-Hao Sun; Hong-Yan Zhao; Guang Ning; Sheng-Tian Li; Jian-Min Liu
Journal:  Front Mol Neurosci       Date:  2018-09-27       Impact factor: 5.639

4.  Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease.

Authors:  Yan-Fang Hou; Chang Shan; Si-Yue Zhuang; Qian-Qian Zhuang; Arijit Ghosh; Ke-Cheng Zhu; Xiao-Ke Kong; Shu-Min Wang; Yan-Ling Gong; Yu-Ying Yang; Bei Tao; Li-Hao Sun; Hong-Yan Zhao; Xing-Zhi Guo; Wei-Qing Wang; Guang Ning; Yan-Yun Gu; Sheng-Tian Li; Jian-Min Liu
Journal:  Microbiome       Date:  2021-01-31       Impact factor: 14.650

Review 5.  Regulation of common neurological disorders by gut microbial metabolites.

Authors:  Jeongho Park; Chang H Kim
Journal:  Exp Mol Med       Date:  2021-12-02       Impact factor: 8.718

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.